Athens Medical C.S.A. (ACS.F)
- Previous Close
1.5500 - Open
1.4400 - Bid 1.4250 x --
- Ask 1.7600 x --
- Day's Range
1.4400 - 1.4400 - 52 Week Range
1.4200 - 2.0800 - Volume
17 - Avg. Volume
18 - Market Cap (intraday)
128.123M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
16.00 - EPS (TTM)
0.0900 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield 0.03 (1.94%)
- Ex-Dividend Date Sep 7, 2023
- 1y Target Est
--
Athens Medical C.S.A., together with its subsidiaries, offers healthcare services in Greece and internationally. The company offers diagnosis and treatment for prostate bladder, kidney, and testicular cancer, as well as interventional cardiology, interventional electrophysiology, and pediatric cardiology; cardiac surgery; robotic surgery, including general, gynecologic, and urology services; and neuro- and spine surgery services. It also provides medical services for range of orthopedics, such as foot and ankle, hand and wrist, hip, knee, shoulder, and spine; sports injuries; plastic Surgeries for face, body, breast, obesity, reconstructive plastic surgery, scar correction, and sex reassignment; bariatric surgery for gastric banding, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch; and chronic diseases, including diabetes, endocrinology, heat failure, high blood pressure, pain management, respiratory system, stroke, and thyroid conditions. In addition, the company operates wellness and prevention centers; and offers medical education, training, and practice services. The company was founded in 1983 and is based in Athens, Greece.
www.iatriko.gr3,230
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ACS.F
Performance Overview: ACS.F
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACS.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACS.F
Valuation Measures
Market Cap
137.91M
Enterprise Value
274.46M
Trailing P/E
16.63
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.52
Price/Book (mrq)
1.24
Enterprise Value/Revenue
1.06
Enterprise Value/EBITDA
7.18
Financial Highlights
Profitability and Income Statement
Profit Margin
3.64%
Return on Assets (ttm)
3.48%
Return on Equity (ttm)
8.68%
Revenue (ttm)
249.37M
Net Income Avi to Common (ttm)
9.07M
Diluted EPS (ttm)
0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
16.34M
Total Debt/Equity (mrq)
138.51%
Levered Free Cash Flow (ttm)
-29.42M